Details for New Drug Application (NDA): 040273
✉ Email this page to a colleague
NDA 040273 describes CHLOROPROCAINE HYDROCHLORIDE, which is a drug marketed by Hikma and Hospira and is included in three NDAs. It is available from two suppliers. Additional details are available on the CHLOROPROCAINE HYDROCHLORIDE profile page.
The generic ingredient in CHLOROPROCAINE HYDROCHLORIDE is chloroprocaine hydrochloride. There are four drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the chloroprocaine hydrochloride profile page.
The generic ingredient in CHLOROPROCAINE HYDROCHLORIDE is chloroprocaine hydrochloride. There are four drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the chloroprocaine hydrochloride profile page.
Summary for 040273
| Tradename: | CHLOROPROCAINE HYDROCHLORIDE |
| Applicant: | Hikma |
| Ingredient: | chloroprocaine hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 040273
| Physiological Effect | Local Anesthesia |
Suppliers and Packaging for NDA: 040273
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CHLOROPROCAINE HYDROCHLORIDE | chloroprocaine hydrochloride | INJECTABLE;INJECTION | 040273 | ANDA | Hikma Pharmaceuticals USA Inc. | 0143-9209 | 0143-9209-10 | 10 VIAL in 1 CARTON (0143-9209-10) / 20 mL in 1 VIAL (0143-9209-01) |
| CHLOROPROCAINE HYDROCHLORIDE | chloroprocaine hydrochloride | INJECTABLE;INJECTION | 040273 | ANDA | Hikma Pharmaceuticals USA Inc. | 0143-9210 | 0143-9210-10 | 10 VIAL in 1 CARTON (0143-9210-10) / 20 mL in 1 VIAL (0143-9210-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 2% | ||||
| Approval Date: | Sep 9, 1998 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 3% | ||||
| Approval Date: | Sep 9, 1998 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
